New Drug for Type 2 Diabetes Shows No Liver Damage

| Jul 1, 1999

In clinical trials, patients taking ACTOS demonstrated no elevation of their liver enzymes when compared to patients taking a placebo.

ACTOS, also known as pioglitazone, helps restore the body's ability to use its own insulin by reducing insulin resistance in people with type 2 diabetes.

More than 4,500 people worldwide have taken part in trials for ACTOS. Efficacy and safety data from trials involving 2,600 patients in the United States were recently submitted to the Food and Drug Administration (FDA) for review. Data presented to the FDA showed that elevated liver enzymes occurred in less than 1 percent of ACTOS-treated patients. Those treated with a placebo had similar results.

Comparing Rezulin and ACTOS, James W. Freston, MD, PhD, professor and director of the Office of Clinical Research, University of Connecticut Health Care, says, "This indicates the liver toxicity seen with another drug in this class is unique to that drug and may not reflect a class effect."

Side effects associated with ACTOS at clinical trials included mild upper respiratory tract infection, headache, sinusitis, muscle pain, tooth disorder and inflammation of the pharynx.

Takeda, the Japanese company that manufactures ACTOS, filed a new drug application with the FDA in January. If approved, ACTOS would be used as a stand-alone therapy, or in combination with sulfonylureas, metformin or insulin for the treatment of type 2 diabetes.

The FDA granted priority review status to ACTOS in March.

Click Here To View Or Post Comments

Categories: Actos, Diabetes, Food, Insulin, Type 2 Issues, Type 2 Medications

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.